positive
31 days agoBillionToOne, diagnostics firm, files for U.S. IPO after narrowing losses

Molecular diagnostics company BillionToOne filed for a U.S. IPO, showing H1 2025 revenue of $125.5 million (vs. $69 million prior year) and a narrowed net loss of $4.2 million. The firm develops non-invasive prenatal tests and liquid biopsies. Underwriters include J.P. Morgan, Wells Fargo, and William Blair.
Reuters• By Sneha Pathak
Explore:Mutual Fund Home
positive
31 days agoBillionToOne, diagnostics firm, files for U.S. IPO after narrowing losses

Molecular diagnostics company BillionToOne filed for a U.S. IPO, showing H1 2025 revenue of $125.5 million (vs. $69 million prior year) and a narrowed net loss of $4.2 million. The firm develops non-invasive prenatal tests and liquid biopsies. Underwriters include J.P. Morgan, Wells Fargo, and William Blair.
Reuters• By Sneha Pathak
Explore:High Return Equity Mutual Fund
about 1 month ago
1 min read
47 words

Diagnostics firm files for U.S. IPO, posts strong revenue growth.
Molecular diagnostics company BillionToOne filed for a U.S. IPO, showing H1 2025 revenue of $125.5 million (vs. $69 million prior year) and a narrowed net loss of $4.2 million. The firm develops non-invasive prenatal tests and liquid biopsies. Underwriters include J.P. Morgan, Wells Fargo, and William Blair.

Molecular diagnostics company BillionToOne filed for a U.S. IPO, showing H1 2025 revenue of $125.5 million (vs. $69 million prior year) and a narrowed net loss of $4.2 million. The firm develops non-invasive prenatal tests and liquid biopsies. Underwriters include J.P. Morgan, Wells Fargo, and William Blair.
Companies:
BillionToOne
Tags:
IPO
healthcare
IPO
healthcare
biotech
BillionToOne
diagnostics
Oct 11, 2025 • 11:33 IST